Associated Genetic Biomarkers
CD274 molecule (CD274; also known as PDL1) is a gene that encodes a protein that is known as programmed cell death 1 ligand 1 (PD-L1). The protein functions in the transmission of the costimulatory signal that is needed for T-cell proliferation. Interaction with the protein inhibits T-cell activation and proliferation. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.
CD274 is altered in 1.01% of all cancers with breast carcinoma, non-small cell lung carcinoma, colorectal adenocarcinoma, malignant glioma, and melanoma having the greatest prevalence of alterations .
The most common alterations in CD274 are CD274 Mutation (0.37%), CD274 Amplification (0.32%), CD274 Loss (0.31%), CD274 R260H (0.02%), and CD274 R260C (0.01%) .
CD274 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain CD274 status as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open).
Trials with CD274 status in the inclusion eligibility criteria most commonly target gastric carcinoma and malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is CD274 Amplification .
Atezolizumab, durvalumab, paclitaxel, and tremelimumab are the most frequent therapies in trials with CD274 as an inclusion criteria .
Significance of CD274 in Diseases
Malignant Solid Tumor +
CD274 is mutated in 2.35% of malignant solid tumor patients .
CD274 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) .
Atezolizumab is the most frequent therapy in malignant solid tumor trials with CD274 alterations as inclusion criteria .
Gastric Carcinoma +
CD274 is mutated in 0.28% of gastric carcinoma patients .
CD274 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
Durvalumab, paclitaxel, and tremelimumab are the most frequent therapies in gastric carcinoma trials with CD274 alterations as inclusion criteria .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.